Emcure says it will continue growth momentum in FY22 by deepening product portfolio, digital focus

Khyati Shah02 Jul, 2021Business

Emcure Pharmaceuticals, one of the fastest-growing drug makers by sales in the domestic market, is planning to strengthen its product portfolio with new launches, line extensions of existing brands and focus on digital sales. The privately held Pune-based company aims to bring first to market specialty or differentiated generic drugs through the company?s own R&D efforts and innovative molecules through in-licensing partnerships.